Lupus Erythematosus, Systemic: Clinical Trials

537 completed, 265 recruiting, 227 unknown, 111 terminated. 329 Phase 2, 311 Phase 1, 229 Not applicable, 156 Phase 3, 79 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	329	Completed 147, Recruiting 57, Terminated 41, Unknown 32, Active not recruiting 21, Not yet recruiting 18, Withdrawn 11, Enrolling by invitation 2
Phase 1	311	Completed 108, Recruiting 97, Not yet recruiting 28, Terminated 22, Unknown 17, Withdrawn 17, Active not recruiting 16, Enrolling by invitation 5, Suspended 1
Not applicable	229	Completed 107, Unknown 46, Recruiting 25, Not yet recruiting 17, Active not recruiting 14, Terminated 12, Withdrawn 4, Enrolling by invitation 3, Suspended 1
Phase 3	156	Completed 54, Terminated 32, Unknown 19, Active not recruiting 17, Recruiting 16, Withdrawn 10, Not yet recruiting 5, Enrolling by invitation 3
Phase 4	79	Completed 33, Unknown 16, Recruiting 14, Withdrawn 7, Active not recruiting 4, Terminated 4, Not yet recruiting 1
Early Phase 1	51	Recruiting 21, Not yet recruiting 8, Unknown 8, Completed 5, Terminated 4, Withdrawn 3, Active not recruiting 1, Suspended 1

Follow this condition Literature Review of Lupus Erythematosus, Systemic trials Research Report on Lupus Erythematosus, Systemic

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus	Phase 1	Withdrawn	Caribou Biosciences, Inc.		2027-12-01	2025-09-19
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress TEAM-LEADS - Lupus, Dermatomyositis, Juvenile	Not applicable	Not yet recruiting	Duke University	25	2027-02-01	2026-05-27
The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE. belantamab mafodotin to the existing stable standard background therapy - SLE - Systemic Lupus Erythematosus	Phase 2	Not yet recruiting	Medical Association for the Study of Cancer Biology and Treatment	12	2027-02-01	2026-09-28
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus	Phase 1	Not yet recruiting	Shenzhen MagicRNA Biotechnology Co., Ltd	12	2026-12-31	2026-08-12
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease	Phase 3	Not yet recruiting	Bristol-Myers Squibb	2300	2026-12-31	2026-09-03
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases anti-CD19 CAR-T cells - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)	Phase 1	Not yet recruiting	Gustave Roussy, Cancer Campus, Grand Paris	6	2026-12-01	2026-09-02
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis	Phase 1 / Phase 2	Not yet recruiting	Pfizer	54	2026-11-19	2026-10-01
Cardiac Imaging in Systemic Disorders: the ORACLES Registry data collection - Lupus		Not yet recruiting	Assistance Publique - Hôpitaux de Paris	1500	2026-11-01	2026-02-13
Effectiveness of Resonance Frequency Breathing Exercises in Patients With Systemic Lupus Erythematosus and Central Sensitization Resonance Frequency Breathing, Standard Exercise Program - Systemic Lupus Erythematosus (SLE), Central Sensitization	Not applicable	Not yet recruiting	Istanbul University - Cerrahpasa	38	2026-11-01	2026-10-13
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Cevostamab, Tocilizumab - Lupus Erythematosus, Systemic	Phase 1	Recruiting	Genentech, Inc.	46	2026-10-31	2026-10-06
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease	Phase 1	Not yet recruiting	Bristol-Myers Squibb	60	2026-10-30	2026-10-14
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS - Systemic Lupus Erythematosus	Phase 1	Not yet recruiting	AstraZeneca	92	2026-10-30	2026-07-07
Deciphering the Genetic Architecture of Autoimmune Diseases Autoimmune Diseases		Recruiting	National Human Genome Research Institute (NHGRI)	300	2026-10-26	2026-10-21
Pain Phenotyping of Rheumatic Diseases - An Observational Study Bedside quantitative sensory testing - Rheumatic Diseases, Lupus Erythematosus, Systemic		Not yet recruiting	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	225	2026-10-26	2026-10-21
A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE] Enpatoran - Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)	Phase 3	Not yet recruiting	EMD Serono Research & Development Institute, Inc.	404	2026-10-15	2026-09-25
Lupus Nephritis Care Pathway Lupus Nephritis (LN) Care Pathway - Lupus Nephritis (LN)	Not applicable	Recruiting	Duke University	25	2026-10-14	2026-10-19
Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus Systemic Lupus Erythematosus, Lupus Nephritis		Not yet recruiting	Assiut University	90	2026-10-01	2026-09-08
Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients Meibomian Gland Dysfunction, Dry Eye Syndromes		Not yet recruiting	Assiut University	150	2026-10-01	2026-09-09
Saphnelo Use in Females of Child-bearing Potential Anifrolumab - Systemic Lupus Erythematosus		Not yet recruiting	AstraZeneca	26000000	2026-10-01	2026-02-25
SNC116 Therapy for Refractory Systemic Lupus Erythematosus SNC116 - Systemic Lupus Erythematosus	Early Phase 1	Not yet recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	28	2026-10-01	2026-09-18

Showing 20 of 1392. Sign in to see all of them.

Narrower conditions

Lupus Nephritis (331)  ·  Autoimmune Diseases (131)  ·  Arthritis, Rheumatoid (117)  ·  Scleroderma, Systemic (102)  ·  Sjogren's Syndrome (67)  ·  Myositis (65)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (44)  ·  Arthritis (36)  ·  Connective Tissue Diseases (36)  ·  Immune System Diseases (35)  ·  Dermatomyositis (32)  ·  Antiphospholipid Syndrome (28)  ·  Scleroderma, Diffuse (27)  ·  Motor Activity (26)

Broader conditions

Skin and Connective Tissue Diseases (1389)  ·  Immune System Diseases (1357)  ·  Connective Tissue Diseases (1356)  ·  Autoimmune Diseases (1261)  ·  Urogenital Diseases (357)  ·  Female Urogenital Diseases and Pregnancy Complications (352)  ·  Female Urogenital Diseases (349)  ·  Male Urogenital Diseases (349)  ·  Urologic Diseases (348)  ·  Kidney Diseases (337)  ·  Glomerulonephritis (320)  ·  Nephritis (318)  ·  Musculoskeletal Diseases (235)  ·  Skin Diseases (192)

Interventions

Cyclophosphamide (61)  ·  Mycophenolic Acid (60)  ·  belimumab (51)  ·  Prednisone (30)  ·  Rituximab (29)  ·  Blood Specimen Collection (28)  ·  Standard of Care (26)  ·  fludarabine (25)  ·  anifrolumab (24)  ·  Azathioprine (21)  ·  Methylprednisolone (19)  ·  Tacrolimus (19)  ·  Adrenal Cortex Hormones (18)  ·  epratuzumab (13)  ·  telitacicept (13)

Sponsors

Assiut University (51)  ·  AstraZeneca (35)  ·  GlaxoSmithKline (31)  ·  Assistance Publique - Hôpitaux de Paris (22)  ·  Amgen (20)  ·  Bristol-Myers Squibb (18)  ·  Novartis Pharmaceuticals (18)  ·  Sohag University (17)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (16)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (16)  ·  Duke University (14)  ·  RenJi Hospital (14)  ·  UCB Pharma (14)  ·  NYU Langone Health (13)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (13)

Countries

United States (532)  ·  China (329)  ·  France (178)  ·  Spain (162)  ·  Germany (135)  ·  Poland (122)  ·  Mexico (121)  ·  Argentina (105)  ·  Brazil (105)  ·  Taiwan (103)  ·  United Kingdom (100)  ·  Canada (97)  ·  South Korea (96)  ·  Italy (90)  ·  Japan (82)

Top investigators

Sarfaraz A Hasni, M.D. (8)  ·  Qiubai Li, Professor (6)

Results publications

PMID 33687069, PMID 37528520, PMID 34628605, PMID 34741731, PMID 34531304, PMID 38775637, PMID 39115551, PMID 39208825, PMID 38216728, PMID 38724182, PMID 40465397, PMID 23213069, PMID 25777546, PMID 31302695, PMID 31660791, PMID 33568389, PMID 33693991, PMID 37228028, PMID 39586304, PMID 18634158, PMID 22087680, PMID 22275291, PMID 22337213, PMID 22553077, PMID 22674457, PMID 23524886, PMID 23681782, PMID 23754628, PMID 24187095, PMID 24254965, PMID 25396065, PMID 25988278, PMID 26138472, PMID 26290435, PMID 26867033, PMID 27099766, PMID 27220348, PMID 27598855, PMID 27723281, PMID 28925994, PMID 29045736, PMID 29381843, PMID 29409143, PMID 29445400, PMID 29450636, PMID 29699792, PMID 31537547, PMID 31790472, PMID 32918459, PMID 33830377

NIH funding

2023 (28), 2025 (12), 2017 (11), 2019 (9), 2015 (7), 2018 (7), 2014 (6), 2016 (5), 2008 (3), 2009 (2), P30AG064199 (2), U01AR042540 (2), K01AR060026 (1), K08CA237619 (1), K23AR078177 (1)